Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis. - Wikidata - wikimedia - TriplyDB

Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis.

Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis.

http://www.wikidata.org/entity/Q37015967

about

New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppression Road to remission: a comprehensive review of therapy in uveitis.CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease.Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis

P2860

Q34175958-215DE17B-9022-4EFA-99A7-38033CDDB5AA Q37936459-30BC6867-4CC1-4087-802A-566298BFF9FF Q38593433-8FFAAEC4-BACD-43D5-9D62-035610CBD767 Q38993229-6231C4E3-DB4C-4FB1-9B0A-8D419F923449

P2860

Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis.

http://www.wikidata.org/entity/Q37015967

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2007

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis.

@en

Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis.

@nl

type

label

Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis.

@en

Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis.

@nl

prefLabel

Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis.

@en

Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis.

@nl

P1433

Q37015967-B432E62F-3114-4D18-89C4-E22BD2F621AA

P1476

Q37015967-25A5F6C1-25D3-43C3-BB2C-6D27CDDB4F8B

P2093

Q37015967-5FAC5902-4C20-4A55-985B-2AA257853F4A

Q37015967-A1C3B018-7093-46C9-8E79-73F67634DDA3

Q37015967-E6886259-FA8E-4966-BF0A-73241F64F820

P2860

Q37015967-033186EE-E4C3-4230-A7EB-A353A4CBBB3D

Q37015967-19730BAA-0368-4AC8-9253-8317338DC82A

Q37015967-20E72558-66F7-467C-8A5E-B27FA9A7E16A

Q37015967-253FBE05-4C49-4BCA-B8DC-5706997FED7B

Q37015967-25F48C18-5C23-49FF-9DB1-24E8D72EAF48

Q37015967-2F036657-E638-4CDC-A65C-D5BB319D24DD

Q37015967-43852FD2-9A6E-4AAE-8986-8020C2E64560

Q37015967-509BE2E0-4C35-41A0-B3B6-7F4902ACFA7A

Q37015967-6947F8A8-3FBF-4659-8650-512AAECF6CEC

Q37015967-7CDCD250-72A1-4DAB-AABC-AC0C44D8C278

P304

Q37015967-29FECA6A-238C-4B57-BF48-CDABF2452971

P31

Q37015967-168373B7-9FE8-48C7-9B6B-B9045C2A6655

P356

Q37015967-4DE9711F-B646-4F20-BF12-12187468B727

P407

Q37015967-5E9B608A-378C-4F69-8F3E-A72C1020C625

P433

Q37015967-CA3121AE-C3BB-4788-9305-EE9D359AD2FC

P478

Q37015967-50D65BF5-66B3-4382-9AE0-1F286DAF6FC2

P577

Q37015967-08F6CA3B-3007-4D52-9943-57C45F2AE275

P698

Q37015967-EC9B6D64-42A6-4587-94DC-A9B3A17EF83C

P356

PHCO.27.12.1693

P1433

Pharmacotherapy

P1476

Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis.

@en

P2093

Carlo A Marra

http://www.w3.org/2001/XMLSchema#string

Jennifer Reynolds

http://www.w3.org/2001/XMLSchema#string

Kam Shojania

http://www.w3.org/2001/XMLSchema#string

P2860

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.

Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial.

Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial.

Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment

Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis?

Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy.

Predicting mortality in patients with rheumatoid arthritis.

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study.

P304

1693-1701

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1592/PHCO.27.12.1693

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2007-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18041889

http://www.w3.org/2001/XMLSchema#string